169 related articles for article (PubMed ID: 12121002)
1. Transcriptomics and proteomics: tools for the identification of novel drug targets and vaccine candidates for tuberculosis.
Betts JC
IUBMB Life; 2002; 53(4-5):239-42. PubMed ID: 12121002
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel vaccine candidates and drug targets against visceral leishmaniasis using proteomics and transcriptomics.
Kumari S; Kumar A; Samant M; Singh N; Dube A
Curr Drug Targets; 2008 Nov; 9(11):938-47. PubMed ID: 18991606
[TBL] [Abstract][Full Text] [Related]
3. Defining the mandate of tuberculosis research in a postgenomic era.
Chakhaiyar P; Hasnain SE
Med Princ Pract; 2004; 13(4):177-84. PubMed ID: 15181320
[TBL] [Abstract][Full Text] [Related]
4. Selecting the components for a safe and efficient tuberculosis subunit vaccine--recent progress and post-genomic insights.
Okkels LM; Doherty TM; Andersen P
Curr Pharm Biotechnol; 2003 Feb; 4(1):69-83. PubMed ID: 12570683
[TBL] [Abstract][Full Text] [Related]
5. Comparative proteome analysis of Mycobacterium tuberculosis and Mycobacterium bovis BCG strains: towards functional genomics of microbial pathogens.
Jungblut PR; Schaible UE; Mollenkopf HJ; Zimny-Arndt U; Raupach B; Mattow J; Halada P; Lamer S; Hagens K; Kaufmann SH
Mol Microbiol; 1999 Sep; 33(6):1103-17. PubMed ID: 10510226
[TBL] [Abstract][Full Text] [Related]
6. Application of a subtractive genomics approach for in silico identification and characterization of novel drug targets in Mycobacterium tuberculosis F11.
Hosen MI; Tanmoy AM; Mahbuba DA; Salma U; Nazim M; Islam MT; Akhteruzzaman S
Interdiscip Sci; 2014 Mar; 6(1):48-56. PubMed ID: 24464704
[TBL] [Abstract][Full Text] [Related]
7. Bioinformatics: use in bacterial vaccine discovery.
Zagursky RJ; Russell D
Biotechniques; 2001 Sep; 31(3):636, 638, 640, passim. PubMed ID: 11570507
[TBL] [Abstract][Full Text] [Related]
8. Application of genomics and proteomics for identification of bacterial gene products as potential vaccine candidates.
Chakravarti DN; Fiske MJ; Fletcher LD; Zagursky RJ
Vaccine; 2000 Nov; 19(6):601-12. PubMed ID: 11090710
[TBL] [Abstract][Full Text] [Related]
9. Comparative mycobacterial genomics as a tool for drug target and antigen discovery.
Cole ST
Eur Respir J Suppl; 2002 Jul; 36():78s-86s. PubMed ID: 12168750
[TBL] [Abstract][Full Text] [Related]
10. New drug targets for Mycobacterium tuberculosis.
Chopra P; Meena LS; Singh Y
Indian J Med Res; 2003 Jan; 117():1-9. PubMed ID: 12866819
[TBL] [Abstract][Full Text] [Related]
11. Structure-based approaches to drug discovery against tuberculosis.
Holton SJ; Weiss MS; Tucker PA; Wilmanns M
Curr Protein Pept Sci; 2007 Aug; 8(4):365-75. PubMed ID: 17696869
[TBL] [Abstract][Full Text] [Related]
12. Proteome-wide subtractive approach to prioritize a hypothetical protein of XDR-Mycobacterium tuberculosis as potential drug target.
Uddin R; Siddiqui QN; Sufian M; Azam SS; Wadood A
Genes Genomics; 2019 Nov; 41(11):1281-1292. PubMed ID: 31388979
[TBL] [Abstract][Full Text] [Related]
13. Exploring functional genomics for the development of novel intervention strategies against tuberculosis.
Rachman H; Kaufmann SH
Int J Med Microbiol; 2007 Nov; 297(7-8):559-67. PubMed ID: 17467338
[TBL] [Abstract][Full Text] [Related]
14. From proteomics to systems biology of bacterial pathogens: approaches, tools, and applications.
Plikat U; Voshol H; Dangendorf Y; Wiedmann B; Devay P; Müller D; Wirth U; Szustakowski J; Chirn GW; Inverardi B; Puyang X; Brown K; Kamp H; Hoving S; Ruchti A; Brendlen N; Peterson R; Buco J; Oostrum Jv; Peitsch MC
Proteomics; 2007 Mar; 7(6):992-1003. PubMed ID: 17370256
[TBL] [Abstract][Full Text] [Related]
15. Towards the proteome of Mycobacterium tuberculosis.
Rosenkrands I; King A; Weldingh K; Moniatte M; Moertz E; Andersen P
Electrophoresis; 2000 Nov; 21(17):3740-56. PubMed ID: 11271494
[TBL] [Abstract][Full Text] [Related]
16. Integrated transcriptome and proteome data: the challenges ahead.
Hack CJ
Brief Funct Genomic Proteomic; 2004 Nov; 3(3):212-9. PubMed ID: 15642185
[TBL] [Abstract][Full Text] [Related]
17. Identification of Novel Potential Vaccine Candidates against Tuberculosis Based on Reverse Vaccinology.
Monterrubio-López GP; González-Y-Merchand JA; Ribas-Aparicio RM
Biomed Res Int; 2015; 2015():483150. PubMed ID: 25961021
[TBL] [Abstract][Full Text] [Related]
18. Systematic review on the proteomic profile of Mycobacterium tuberculosis exposed to drugs.
Campanerut-Sá PAZ; Ghiraldi-Lopes LD; Meneguello JE; Teixeira JJV; Scodro RBL; Siqueira VLD; Svidzinski TIE; Pavan FR; Cardoso RF
Proteomics Clin Appl; 2017 Dec; 11(11-12):. PubMed ID: 28627738
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of potential druggable targets among hypothetical proteins of extensively drug resistant Mycobacterium tuberculosis (XDR KZN 605) through subtractive genomics approach.
Uddin R; Siddiqui QN; Azam SS; Saima B; Wadood A
Eur J Pharm Sci; 2018 Mar; 114():13-23. PubMed ID: 29174549
[TBL] [Abstract][Full Text] [Related]
20. Proteomic profile of Mycobacterium tuberculosis after eupomatenoid-5 induction reveals potential drug targets.
Ghiraldi-Lopes LD; Campanerut-Sá PA; Meneguello JE; Seixas FA; Lopes-Ortiz MA; Scodro RB; Pires CT; da Silva RZ; Siqueira VL; Nakamura CV; Cardoso RF
Future Microbiol; 2017 Aug; 12():867-879. PubMed ID: 28686056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
